Lantern Pharma's LP-284 gets FDA orphan drug status for soft tissue sarcoma Jan 20, 2026 08:04AM
Lantern Pharma establishes AI center in India to expand RADR platform Jan 12, 2026 09:01AM
New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television Dec 27, 2025 05:00PM
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST Nov 8, 2025 11:40AM
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows Nov 7, 2025 09:00AM


Oct 28, 2025 08:50AM Lantern Pharma reports complete response in DLBCL patient after CAR-T failure
Oct 3, 2025 09:00AM Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Sep 16, 2025 08:27AM Lantern Pharma (LTRN) Halted, News Pending
Sep 3, 2025 09:44AM Lantern Pharma completes FDA meeting for pediatric brain cancer trial
Aug 19, 2025 08:00AM RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26
Aug 13, 2025 06:08PM Lantern Pharma (LTRN) Tops Q2 EPS by 13c
Aug 6, 2025 08:30AM FDA clears Starlight Therapeutics brain cancer trial for STAR-001 combo
Aug 4, 2025 08:55AM Lantern Pharma releases AI tool for blood-brain barrier prediction
Jul 25, 2025 09:00AM Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Jul 21, 2025 08:20AM Lantern Pharma receives EU patent allowance for AI-developed cancer drug LP-284
Jul 15, 2025 09:40AM Lantern Pharma launches AI module for cancer combination therapy
May 29, 2025 08:35AM Lantern Pharma (LTRN) announces promising data for LP-184 in ATRT
May 15, 2025 05:03PM Lantern Pharma (LTRN) Reports Q1 Loss of $0.42
May 12, 2025 09:00AM Lantern Pharma (LTRN) Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
Feb 19, 2025 08:02AM Lantern Pharma (LTRN) Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
Jan 27, 2025 08:04AM Lantern Pharma (LTRN) Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
Dec 3, 2024 08:05AM Lantern Pharma (LTRN) Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer
Nov 26, 2024 08:45AM Lantern Pharma (LTRN) and Starlight Therapeutics Present LP-184 Phase 1b Trial Design and Preclinical Data
Nov 7, 2024 04:49PM Lantern Pharma (LTRN) Tops Q3 EPS by 14c
Oct 15, 2024 09:07AM Lantern Pharma's (LTRN) Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
Sep 23, 2024 08:00AM Lantern Pharma (LTRN) Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
Jul 10, 2024 08:32AM Lantern Pharma (LTRN) Achieves Key Milestone Towards Development of Molecular Diagnostic with LP-184
Jun 12, 2024 07:31AM Lantern Pharma (LTRN) Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284